BioGlue® in 2011: What is its role in cardiac surgery?

Castigliano Bhamidipati, Joseph S. Coselli, Scott A. LeMaire

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BioGlue surgical adhesive was developed as an adjunct for achieving hemostasis during cardiovascular surgery, and it was approved for use in the United States by the Food and Drug Administration in 2001. When applied to cardiovascular tissues, the glutaraldehyde and bovine serum albumin that comprise BioGlue produce strong crosslinking that bonds tissues and seals defects. These features have made BioGlue particularly well suited for preventing bleeding from fragile cardiovascular anastomoses such as those inherent in the repair of acute aortic dissection. Over the 10-year period since its approval, several studies and clinical reports have illuminated the relative risks and benefits of using BioGlue during cardiovascular operations. Understanding these merits and limitations of BioGlue is essential to ensuring its safe and effectiveuse.

Original languageEnglish (US)
JournalJournal of Extra-Corporeal Technology
Volume44
Issue number1
StatePublished - Aug 8 2012
Externally publishedYes

Fingerprint

Thoracic Surgery
Glutaral
United States Food and Drug Administration
Bovine Serum Albumin
Hemostasis
Adhesives
Dissection
Bio-glue
Hemorrhage

Keywords

  • BioGlue
  • Review
  • Surgery
  • Surgical adhesives

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Cardiology and Cardiovascular Medicine
  • Health Professions (miscellaneous)

Cite this

BioGlue® in 2011 : What is its role in cardiac surgery? / Bhamidipati, Castigliano; Coselli, Joseph S.; LeMaire, Scott A.

In: Journal of Extra-Corporeal Technology, Vol. 44, No. 1, 08.08.2012.

Research output: Contribution to journalArticle

@article{5b897ae5ba4a43a594a078f370d17340,
title = "BioGlue{\circledR} in 2011: What is its role in cardiac surgery?",
abstract = "BioGlue surgical adhesive was developed as an adjunct for achieving hemostasis during cardiovascular surgery, and it was approved for use in the United States by the Food and Drug Administration in 2001. When applied to cardiovascular tissues, the glutaraldehyde and bovine serum albumin that comprise BioGlue produce strong crosslinking that bonds tissues and seals defects. These features have made BioGlue particularly well suited for preventing bleeding from fragile cardiovascular anastomoses such as those inherent in the repair of acute aortic dissection. Over the 10-year period since its approval, several studies and clinical reports have illuminated the relative risks and benefits of using BioGlue during cardiovascular operations. Understanding these merits and limitations of BioGlue is essential to ensuring its safe and effectiveuse.",
keywords = "BioGlue, Review, Surgery, Surgical adhesives",
author = "Castigliano Bhamidipati and Coselli, {Joseph S.} and LeMaire, {Scott A.}",
year = "2012",
month = "8",
day = "8",
language = "English (US)",
volume = "44",
journal = "Journal of Extra-Corporeal Technology",
issn = "0022-1058",
publisher = "American Society of Extra-Corporeal Technology",
number = "1",

}

TY - JOUR

T1 - BioGlue® in 2011

T2 - What is its role in cardiac surgery?

AU - Bhamidipati, Castigliano

AU - Coselli, Joseph S.

AU - LeMaire, Scott A.

PY - 2012/8/8

Y1 - 2012/8/8

N2 - BioGlue surgical adhesive was developed as an adjunct for achieving hemostasis during cardiovascular surgery, and it was approved for use in the United States by the Food and Drug Administration in 2001. When applied to cardiovascular tissues, the glutaraldehyde and bovine serum albumin that comprise BioGlue produce strong crosslinking that bonds tissues and seals defects. These features have made BioGlue particularly well suited for preventing bleeding from fragile cardiovascular anastomoses such as those inherent in the repair of acute aortic dissection. Over the 10-year period since its approval, several studies and clinical reports have illuminated the relative risks and benefits of using BioGlue during cardiovascular operations. Understanding these merits and limitations of BioGlue is essential to ensuring its safe and effectiveuse.

AB - BioGlue surgical adhesive was developed as an adjunct for achieving hemostasis during cardiovascular surgery, and it was approved for use in the United States by the Food and Drug Administration in 2001. When applied to cardiovascular tissues, the glutaraldehyde and bovine serum albumin that comprise BioGlue produce strong crosslinking that bonds tissues and seals defects. These features have made BioGlue particularly well suited for preventing bleeding from fragile cardiovascular anastomoses such as those inherent in the repair of acute aortic dissection. Over the 10-year period since its approval, several studies and clinical reports have illuminated the relative risks and benefits of using BioGlue during cardiovascular operations. Understanding these merits and limitations of BioGlue is essential to ensuring its safe and effectiveuse.

KW - BioGlue

KW - Review

KW - Surgery

KW - Surgical adhesives

UR - http://www.scopus.com/inward/record.url?scp=84864321114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864321114&partnerID=8YFLogxK

M3 - Article

C2 - 22730865

AN - SCOPUS:84864321114

VL - 44

JO - Journal of Extra-Corporeal Technology

JF - Journal of Extra-Corporeal Technology

SN - 0022-1058

IS - 1

ER -